FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564755932> ?p ?o ?g. }

• W2564755932 endingPage "S99" @default.
• W2564755932 startingPage "S98" @default.
• W2564755932 abstract "Cerebral X-linked adrenoleukodystrophy (CALD) is a severe brain demyelinating disease caused by a deficiency in ALD protein (ALDP), an adenosine triphosphate-binding cassette transporter encoded by the ABCD1 gene. Brain lesion progression can be halted by allogeneic hematopoietic cell transplantation (HCT). We used gene transfer with a third-generation SIN-lentivirus vector with MND as an internal promoter expressing the ABCD1 gene (Lenti-D vector) to transduce autologous hematopoietic stem cells (HSCs) in 17 patients with CALD and gadolinium enhancement on brain MRI lacking HLA antigen-matched sibling donors (ages 4-13y; mean, 5.8y). At enrollment, Neurological Function Score (NFS) was 0 in all subjects and median Loes Score was 2 (1-8). Cells were transduced under GMP conditions at an academic site or a central contract manufacturing site and the drug product frozen, certified for release and transported to study sites for infusion. 6.0-20.4X10e6 CD34+ cells/kg of drug product were infused after myeloablative conditioning with busulfan and cyclophosphamide. Vector copy number (VCN) in infused cells was 0.5 to 2.5. As of 10/1/15, 6 subjects had 12-23m follow up, 8 had 6-12m, and 3 had <6m. All patients engrafted with gene marked cells. Time to absolute neutrophil count (ANC)>500/µl was 19-38d (without G-CSF; N=4) and 10-19d (with G-CSF started day +5; N=13). Time to platelet counts >20,000/µl without platelet transfusions was 14-54 days. Median VCN in DP and peripheral blood leukocytes (PBL) and proportions of PBLs and CD14+ myeloid cells expressing ALDP as detected by flow cytometric analysis are below. Integration site analysis shows polyclonal reconstitution in all subjects, with no indication of vector mediated clonal skewing to date. Neurologic outcomes (NFS and major functional disabilities [MFD]) were assessed at each study visit. MRI results (Loes Score and gadolinium enhancement) were periodically reviewed centrally. MRI data were available on 8 subjects with ≥6m follow up. All 8 had resolution of gadolinium enhancement on brain MRI. Median change in Loes Score was 1 (0-6), and no patient demonstrated progression of NFS. Two SAEs were assessed possibly related to Lenti-D drug product (DP), BK virus cystitis and tachycardia. To date, the safety profile of Lenti-D DP appears consistent with myeloablative conditioning. These early results demonstrate feasibility of centralized manufacturing for a HSC gene therapy trial and short-term safety and efficacy of gene therapy in CALD. Assessment of long-term outcomes and safety continues. Tabled 1Median (IQR) VCN and ALDP expression over timeVCN% PBLs expressing ALDP% CD14+ expresing ALDPPretreatmentDP:1.0 (0.6, 1.6), N=170.9 (0.5, 1.5), N=171.0 (0.7, 1.6), N=116 monthsPBL:0.5 (0.3, 1.0), N=1313.5 (9.3, 20.1), N=1226.4 (14.0, 36.0), N=1012 monthsPBL:0.7 (0.4, 0.8), N=922.9 (18.8, 29.5), N=532.5 (22.3, 45.2), N=6 Open table in a new tab" @default.
• W2564755932 created "2017-01-06" @default.
• W2564755932 creator A5011992727 @default.
• W2564755932 creator A5014639393 @default.
• W2564755932 creator A5014678847 @default.
• W2564755932 creator A5015856478 @default.
• W2564755932 creator A5025134147 @default.
• W2564755932 creator A5029064436 @default.
• W2564755932 creator A5033661466 @default.
• W2564755932 creator A5036919823 @default.
• W2564755932 creator A5041773724 @default.
• W2564755932 creator A5050971129 @default.
• W2564755932 creator A5051176063 @default.
• W2564755932 creator A5051468151 @default.
• W2564755932 creator A5056346259 @default.
• W2564755932 creator A5060056123 @default.
• W2564755932 creator A5062100186 @default.
• W2564755932 creator A5067009658 @default.
• W2564755932 creator A5068248790 @default.
• W2564755932 creator A5069149045 @default.
• W2564755932 creator A5069809093 @default.
• W2564755932 creator A5073418464 @default.
• W2564755932 creator A5077588523 @default.
• W2564755932 creator A5079132405 @default.
• W2564755932 creator A5081627481 @default.
• W2564755932 creator A5085511830 @default.
• W2564755932 creator A5089982991 @default.
• W2564755932 date "2016-05-01" @default.
• W2564755932 modified "2023-10-17" @default.
• W2564755932 title "250. A Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy with Lenti-D TM Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy" @default.
• W2564755932 doi "https://doi.org/10.1016/s1525-0016(16)33059-3" @default.
• W2564755932 hasPublicationYear "2016" @default.
• W2564755932 type Work @default.
• W2564755932 sameAs 2564755932 @default.
• W2564755932 citedByCount "2" @default.
• W2564755932 countsByYear W25647559322017 @default.
• W2564755932 countsByYear W25647559322023 @default.
• W2564755932 crossrefType "journal-article" @default.
• W2564755932 hasAuthorship W2564755932A5011992727 @default.
• W2564755932 hasAuthorship W2564755932A5014639393 @default.
• W2564755932 hasAuthorship W2564755932A5014678847 @default.
• W2564755932 hasAuthorship W2564755932A5015856478 @default.
• W2564755932 hasAuthorship W2564755932A5025134147 @default.
• W2564755932 hasAuthorship W2564755932A5029064436 @default.
• W2564755932 hasAuthorship W2564755932A5033661466 @default.
• W2564755932 hasAuthorship W2564755932A5036919823 @default.
• W2564755932 hasAuthorship W2564755932A5041773724 @default.
• W2564755932 hasAuthorship W2564755932A5050971129 @default.
• W2564755932 hasAuthorship W2564755932A5051176063 @default.
• W2564755932 hasAuthorship W2564755932A5051468151 @default.
• W2564755932 hasAuthorship W2564755932A5056346259 @default.
• W2564755932 hasAuthorship W2564755932A5060056123 @default.
• W2564755932 hasAuthorship W2564755932A5062100186 @default.
• W2564755932 hasAuthorship W2564755932A5067009658 @default.
• W2564755932 hasAuthorship W2564755932A5068248790 @default.
• W2564755932 hasAuthorship W2564755932A5069149045 @default.
• W2564755932 hasAuthorship W2564755932A5069809093 @default.
• W2564755932 hasAuthorship W2564755932A5073418464 @default.
• W2564755932 hasAuthorship W2564755932A5077588523 @default.
• W2564755932 hasAuthorship W2564755932A5079132405 @default.
• W2564755932 hasAuthorship W2564755932A5081627481 @default.
• W2564755932 hasAuthorship W2564755932A5085511830 @default.
• W2564755932 hasAuthorship W2564755932A5089982991 @default.
• W2564755932 hasBestOaLocation W25647559321 @default.
• W2564755932 hasConcept C104317684 @default.
• W2564755932 hasConcept C109159458 @default.
• W2564755932 hasConcept C111599444 @default.
• W2564755932 hasConcept C126322002 @default.
• W2564755932 hasConcept C127078168 @default.
• W2564755932 hasConcept C150903083 @default.
• W2564755932 hasConcept C170493617 @default.
• W2564755932 hasConcept C203014093 @default.
• W2564755932 hasConcept C207001950 @default.
• W2564755932 hasConcept C26291073 @default.
• W2564755932 hasConcept C2776694085 @default.
• W2564755932 hasConcept C2776755627 @default.
• W2564755932 hasConcept C2777150068 @default.
• W2564755932 hasConcept C2777408962 @default.
• W2564755932 hasConcept C2780611847 @default.
• W2564755932 hasConcept C28328180 @default.
• W2564755932 hasConcept C2911091166 @default.
• W2564755932 hasConcept C32470452 @default.
• W2564755932 hasConcept C40767141 @default.
• W2564755932 hasConcept C55493867 @default.
• W2564755932 hasConcept C71924100 @default.
• W2564755932 hasConcept C86803240 @default.
• W2564755932 hasConcept C95444343 @default.
• W2564755932 hasConcept C98274493 @default.
• W2564755932 hasConceptScore W2564755932C104317684 @default.
• W2564755932 hasConceptScore W2564755932C109159458 @default.
• W2564755932 hasConceptScore W2564755932C111599444 @default.
• W2564755932 hasConceptScore W2564755932C126322002 @default.
• W2564755932 hasConceptScore W2564755932C127078168 @default.
• W2564755932 hasConceptScore W2564755932C150903083 @default.
• W2564755932 hasConceptScore W2564755932C170493617 @default.
• W2564755932 hasConceptScore W2564755932C203014093 @default.
• W2564755932 hasConceptScore W2564755932C207001950 @default.
• W2564755932 hasConceptScore W2564755932C26291073 @default.

• next